Cogent Biosciences (COGT) Receives a Buy from SVB Securities

SVB Securities analyst Research Report) on August 9 and set a price target of $20.00. The company’s shares closed yesterday at $13.81.

Liu covers the Healthcare sector, focusing on stocks such as Cogent Biosciences, Arvinas Holding Company, and Nurix Therapeutics. According to TipRanks, Liu has an average return of 10.5% and a 57.58% success rate on recommended stocks.

Cogent Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $17.33.

See the top stocks recommended by analysts >>

The company has a one-year high of $13.00 and a one-year low of $3.79. Currently, Cogent Biosciences has an average volume of 3.06M.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Unum Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel immunotherapy products designed to harness the power of a patient’s immune system to cure cancer. The firm’s technologies include Antibody-Coupled T-cell Receptor, which is a chimeric protein that binds to tumor targeting antibodies. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Cambridge, MA.

Read More on COGT:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More